Toxys’ Post

The development of biologically relevant, predictive cell-based assays for compound screening and toxicity assessment is a major challenge in drug discovery. See how the FLIPR® Penta and ImageXpress® Micro Confocal Systems can be used to obtain robust multi-parameter cytotoxicity data in this video on #toxicity studies of iPSC-derived cardiomyocytes and neuronal spheroids. Watch the video ➡️ https://bit.ly/48HOAIE #drugdevelopment #kineticscreening #toxicology #cellviability 

🌟Checking Our Interesting Article🌟 📚Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity 🔗https://lnkd.in/ePdUMGmy 👨🔬 By Prof. Wim Martinet et al. MDPI University of Antwerp Ghent University #Molecular #Toxicology #doxorubicin #cardiooncology #arterialstiffness #endothelialdysfunction

The MultiFlow® assay sits within our range of Clastogen & Aneugen screening options. Using multiple biomarkers within a single flow cytometry-based experiment, the MultiFlow® assay can be used to distinguish between clastogenic and aneugenic modes of action, and also identify potentially misleading positives that might be secondary to cytotoxicity. Speak to a member of our team today to find out how this assay can support your next study: https://lnkd.in/ddSZkTp #Toxicology #CRO

Chemotherapeutic agents have been widely associated with risk of cardiac toxicity. That's why we propose to identify and to grade your drugs earlier in your development process. Let's start a discussion on your project!

Our aProximate™ Proximal tubule assay-ready plates support a myriad of different applications including: - Drug transporter studies - ADME/DMPK evaluations - Toxicity studies Speak to our kidney experts today about our assay-ready plates and try them out. https://lnkd.in/eGcv44FG #biotech #toxicology #ADME

The Big Blue® transgenic mutation models ensure the continued market provision of the Big Blue® transgenic assays for companies requiring mutagenicity assessment under the OECD 488 guideline. These studies play a central role in enabling risk assessments for materials where pre-existing data indicates a potential mutagenicity risk to human health and the environment. Speak to a member of our team today to find out how the Big Blue® studies can support your next project: https://lnkd.in/ddSZkTp #Toxicology #CRO

Our aProximate™ Proximal tubule assay-ready plates support a myriad of different applications including: - Drug transporter studies - ADME/DMPK evaluations - Toxicity studies Speak to our kidney experts today about our assay-ready plates and try them out. https://lnkd.in/eGcv44FG #biotech #toxicology #ADME

Our MPS flow model is: - Utilizing freshly isolated PTCs - Retaining all key renal transporters and maintaining functionality - High through put Find out more from our kidney experts: https://lnkd.in/gtEnXFQU #toxicology #ADME #biotech

Newcells aProximate™ proximal tubule cell model and glomerulus models are ideal tools for assessing kidney safety/toxicity. In our studies we quantify FDA-approved kidney toxicity biomarkers, such as KIM-1, NGAL and clusterin. Contact us for more information: https://lnkd.in/df_z9ZnR #drugdiscovery #biotech #organonachip #toxicology #ADME

In a new #Toxicology Research article, “A mechanistic #biomarker investigation of fialuridine hepatotoxicity using the chimeric TK-NOG Hu-liver mouse model and #invitro micropatterned #hepatocyte cocultures,” the #HEPATOPAC model is shown to provide improved IVIVE data compared to conventional models. Fialuridine caused deaths in a human clinical trial because of liver toxicity that was not predicted in #preclinical safety studies. This paper looks at different models for their ability to identify nucleosides with similar mitochondrial toxicity mechanistic liability potential. Read more: https://hubs.ly/Q02h-ZVx0